Eli Lilly (LLY) recently entered a collaboration with Gate Bioscience to develop molecular gate therapeutics, a move that ...

Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new ...

Collaboration combines Gate Bioscience's Molecular Gate drug discovery engine with Lilly's expertise in small molecule therapeutics. Company to receive an upfront payment, an equity investment, ...

Gate Bioscience Inc. has entered a collaboration and license agreement with Eli Lilly and Co. to discover, develop and ...

Eli Lilly (LLY) recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a ...

Lilly priced its drug at $695.65 per vial, or about $32,000 for 12-months of treatment consisting of 13 infusions. That’s slightly higher than Eisai’s Leqembi, which costs $26,500 a year.

On Wall Street, Eli Lilly has a consensus Strong Buy rating with 16 Buys, one Hold, and one Sell rating. LLY’s average stock price target is $1,003.14, indicating almost 40% upside potential in ...